Intercepting Blood Cancers
12 - 14 April, 2024
Lisbon, Portugal
The Intercepting Blood Cancers Workshop (IBC) 2024 will provide a unique, interactive platform for presentations on key clinical trial data and expert clinical insights for early interventions in blood cancers and how this impacts outcomes for patients; three key topic tracks will include:
- Monoclonal B lymphocytosis (MBL), chronic lymphocytic leukemia (CLL) and low-grade lymphoma
- Myelodysplastic syndromes (MDS) and clonal hematopoiesis of indeterminate potential (CHIP)
- Multiple myeloma (MM), smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS)
The current aims of the workshop are to:
- Describe current knowledge of blood cancer precursors and how these might enable early clinical intervention
- Discuss ongoing clinical studies and any available data from these on treatment interceptions for early-stage blood cancers
- Share knowledge and clinical insights between blood cancer disciplines and therapy areas
- Plan for publication and dissemination of consensus findings from discussions across each of the key topic tracks

Supporter Opportunities
If you are interested in becoming a supporter of the IBC Workshop, please contact us
The IBC 2023 Workshop was supported by:
Gold Supporters


Silver Supporters



Supporters


